How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

346 results for

Tipranavir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Surveillance and Treatment of Prisoners With Hepatitis C

inhibitors: Tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), emtricitabine (FTC)Non-nucleoside reverse transcriptase inhibitors: Rilpivirine Protease inhibitors: Atazanavir, darunavir, lopinavir, ritonavir Integrase inhibitors: Dolutegravir, raltegravir, elvitegravir/cobicistat Contraindicated ARV include: Efavirenz (50% reduction in velpatasvir exposure) Didanosine Zidovudine Tipranavir Other ARV agents may be permissible at the time of study commencement pending further drug-drug

2014 Clinical Trials

142. A Novel Compound for Alcoholism Treatment

, azithromycin, captopril, carvedilol, clarithromycin, conivaptan, cyclosporine, diltiazem, dronedarone, erythromycin, felodipine, itraconazole, ketoconazole, lopinavir and ritonavir, quercetin, quinidine, ranolazine, verapamil Inducers: Avasimibe, carbamazepine, phenytoin, rifampin, St John s wort, tipranavir/ritonavir [From Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers, table 12, from http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources

2014 Clinical Trials

143. Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers

: Completed First Posted : July 21, 2014 Last Update Posted : July 21, 2014 Sponsor: Boehringer Ingelheim Information provided by (Responsible Party): Boehringer Ingelheim Study Details Study Description Go to Brief Summary: Study to determine the effects of single-dose and steady-state TPV/RTV 500/200 mg on the steady-state pharmacokinetics of fluconazole Condition or disease Intervention/treatment Phase Healthy Drug: Tipranavir (TPV) Drug: Ritonavir (RTV) Drug: Fluconazole (FCZ) Phase 1 Study Design Go (...) Completion Date : July 2003 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: TPV + RTV + FCZ Drug: Tipranavir (TPV) 500 mg bid on days 7-14 Drug: Ritonavir (RTV) 200 mg bid on days 7-14 Drug: Fluconazole (FCZ) 200 mg loading dose on day 1, followed by 100 mg qd until day 13 Outcome Measures Go to Primary Outcome Measures : Area under plasma concentration time curve from 0-24 hours (AUC0-24h) for FCZ [ Time

2014 Clinical Trials

144. Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers

provided by (Responsible Party): Boehringer Ingelheim Study Details Study Description Go to Brief Summary: Study to assess the steady-state pharmacokinetics of carbamazepine (CBZ) at 200 mg or 100 mg twice daily, depending on tolerability, and administered alone and in combination with tipranavir/ritonavir (TPV/r) after a single dose (500/200 mg) and at steady-state (500/200 mg twice-daily) Condition or disease Intervention/treatment Phase Healthy Drug: Carbamazepine Drug: Tipranavir Drug: Ritonavir (...) Actual Primary Completion Date : June 2006 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: CBZ - TPB/r+CBZ Days 1-14: carbamazepine (CBZ) twice daily Days 15-22: CBZ twice daily plus TPV/r twice daily Drug: Carbamazepine Drug: Tipranavir Drug: Ritonavir Outcome Measures Go to Primary Outcome Measures : Area under the concentration-time curve of Carbamazepine in plasma over the time interval t0h to t12h

2014 Clinical Trials

145. COPANLISIB (BAY80-6946) Drug-drug Interaction Study in Advanced Solid Tumor Patients

by CYP3A4, such as dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine), atazanavir, darunavir, fosamprenavir, ritonavir-boosted saquinavir, saquinavir, or tipranavir Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number

2014 Clinical Trials

146. Conserved hydrogen-bonding network of P2 bis-tetrahydrofuran containing HIV-1 protease inhibitors (PI) with protease active site amino acid-backbone aid in their activity against PI-resistant HIV. Full Text available with Trip Pro

], 0.029 and 0.002 μM, respectively) against a multidrug-resistant clinical isolate of HIV-1 (HIVA02) compared to ritonavir (RTV; EC50, >1.0 μM) and tipranavir (TPV; EC50, 0.364 μM). Additionally, GRL008 showed potent antiviral activity against an HIV-1 variant selected in the presence of DRV over 20 passages (HIVDRV(R)P20), with a 2.6-fold increase in its EC50 (0.097 μM) compared to its corresponding EC50 (0.038 μM) against wild-type HIV-1NL4-3 (HIVWT). Based on X-ray crystallographic analysis, both

2014 Antimicrobial Agents and Chemotherapy

147. Teratology and Drug Use During Pregnancy (Diagnosis)

damage (probably reversible) to immature nephrons. In addition, inner ear damage or hearing defects have been induced in utero in rats and guinea pigs exposed to streptomycin and/or kanamycin. Antiretrovirals (Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zalcitabine, Zidovudine, Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir/ritonavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir, Raltegravir

2014 eMedicine.com

148. HIV Nephropathy (Diagnosis)

, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir) may precipitate nephrolithiasis. A classic form of this is crystalluria with the older agent indinavir, which occurs independently of renal function; however, the stones resolve after cessation of indinavir therapy. A study by Rockwood et al found that the rate of kidney stones was 7.3 per 1000 patient-years in patients receiving ritonavir-boosted atazanavir compared with 1.9 per 1000 patient years

2014 eMedicine.com

149. Teratology and Drug Use During Pregnancy (Overview)

damage (probably reversible) to immature nephrons. In addition, inner ear damage or hearing defects have been induced in utero in rats and guinea pigs exposed to streptomycin and/or kanamycin. Antiretrovirals (Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zalcitabine, Zidovudine, Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir/ritonavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir, Raltegravir

2014 eMedicine.com

150. HIV Nephropathy (Treatment)

, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir) may precipitate nephrolithiasis. A classic form of this is crystalluria with the older agent indinavir, which occurs independently of renal function; however, the stones resolve after cessation of indinavir therapy. A study by Rockwood et al found that the rate of kidney stones was 7.3 per 1000 patient-years in patients receiving ritonavir-boosted atazanavir compared with 1.9 per 1000 patient years

2014 eMedicine.com

152. Teratology and Drug Use During Pregnancy (Treatment)

damage (probably reversible) to immature nephrons. In addition, inner ear damage or hearing defects have been induced in utero in rats and guinea pigs exposed to streptomycin and/or kanamycin. Antiretrovirals (Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zalcitabine, Zidovudine, Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir/ritonavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir, Raltegravir

2014 eMedicine.com

153. HIV Nephropathy (Overview)

, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir) may precipitate nephrolithiasis. A classic form of this is crystalluria with the older agent indinavir, which occurs independently of renal function; however, the stones resolve after cessation of indinavir therapy. A study by Rockwood et al found that the rate of kidney stones was 7.3 per 1000 patient-years in patients receiving ritonavir-boosted atazanavir compared with 1.9 per 1000 patient years

2014 eMedicine.com

154. HIV Nephropathy (Follow-up)

, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir) may precipitate nephrolithiasis. A classic form of this is crystalluria with the older agent indinavir, which occurs independently of renal function; however, the stones resolve after cessation of indinavir therapy. A study by Rockwood et al found that the rate of kidney stones was 7.3 per 1000 patient-years in patients receiving ritonavir-boosted atazanavir compared with 1.9 per 1000 patient years

2014 eMedicine.com

156. Teratology and Drug Use During Pregnancy (Follow-up)

damage (probably reversible) to immature nephrons. In addition, inner ear damage or hearing defects have been induced in utero in rats and guinea pigs exposed to streptomycin and/or kanamycin. Antiretrovirals (Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zalcitabine, Zidovudine, Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir/ritonavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir, Raltegravir

2014 eMedicine.com

157. Body Fluid Exposures (Follow-up)

agents are not recommended to be used for PEP because of their potential toxicity: Nevirapine Didanosine Nelfinavir Tipranavir High-risk exposures If the source is known to have HIV and is undergoing HIV treatment, an alternate regimen may be required because of the possibility of resistance; if possible, an HIV specialist should be consulted (see Consultations). Adherence Failure to complete courses of recommended regimens has been due to adverse effects, such as headache, diarrhea, or nausea

2014 eMedicine Emergency Medicine

158. Body Fluid Exposures (Treatment)

agents are not recommended to be used for PEP because of their potential toxicity: Nevirapine Didanosine Nelfinavir Tipranavir High-risk exposures If the source is known to have HIV and is undergoing HIV treatment, an alternate regimen may be required because of the possibility of resistance; if possible, an HIV specialist should be consulted (see Consultations). Adherence Failure to complete courses of recommended regimens has been due to adverse effects, such as headache, diarrhea, or nausea

2014 eMedicine Emergency Medicine

159. Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

of EVG in the applicable country. Drug: EVG Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily Other Name: Vitekta® Drug: Background regimen Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants < 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed (...) of EVG in the applicable country. Drug: EVG Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily Other Name: Vitekta® Drug: Background regimen Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants < 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed

2013 Clinical Trials

160. Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours

) greater than 470 msec at 2 or more time points within a 24 hour period or family history of long QT syndrome. Concomitant medication contraindicated for use with rifampicin (including, but not limited to): atazanavir, darunavir, fosamprenavir, ritonavir-boosted saquinavir, saquinavir, or tipranavir. Patients who have jaundice. Patients who weigh less than 50 kg. Clinical judgment by the investigator that the patient should not participate in the study. Contacts and Locations Go to Information from

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>